Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Maturation and Phenotyping of Idiopathic Dilated Cardiomyopathy Patient-Derived iPSC-Cardiomyocytes
EF 2021-22
Résumé
With a 5-year survival rate of 50% following diagnosis, there is a need for improved diagnostic and treatment approaches for heart failure (HF). The second most common cause of HF is dilated cardiomyopathy (DCM), a disease affecting the hearts ability to deliver oxygenated blood to the rest of the body. In many cases, DCM is idiopathic, with no clear cause. Idiopathic DCM is still poorly understood and manifests itself differently between patients, making it difficult to form early diagnosis, guide treatment plans, or inform therapeutic development. Our objective is to better understand different phenotypes of idiopathic DCM using patient-derived, induced pluripotent stem cell-cardiomyocytes (iPSC-CMs) to model DCM in a ;dish. We hypothesize that the phenotypic properties and underlying molecular mechanisms in DCM iPSC-CMs compared to age-matched controls can stratify DCM patients into defined disease subtypes. To achieve our objective, we aim to 1) generate iPSCs from both male and female DCM patients of varied ethnic backgrounds and differentiate them into CMs, 2) induce phenotypically immature patient-specific iPSC-CMs towards a more mature and disease-relevant phenotype, and 3) use high-content imaging to characterize phenotypic and morphological differences between iPSC-CMs from DCM patients and age-matched control subjects. This workflow will allow us to better understand DCM disease evolution and cluster idiopathic DCM patients into defined disease subtypes, paving the way for more personalized treatments, predicting individual responses to current therapies, and helping to identify novel drug targets to ultimately improve the quality and duration of life for idiopathic DCM patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466944
Name
Jiang Alyson
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Maturation and Phenotyping of Idiopathic Dilated Cardiomyopathy Patient-Derived iPSC-Cardiomyocytes
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cardiomyocytes; Cell Morphology; Dilated Cardiomyopathy; Disease Modeling; Heart Failure; Induced Pluripotent Stem Cells; Ipsc-Cardiomyocyte Maturation; Patient Clustering; Personalized Medicine; Phenotyping
Abstract
With a 5-year survival rate of 50% following diagnosis, there is a need for improved diagnostic and treatment approaches for heart failure (HF). The second most common cause of HF is dilated cardiomyopathy (DCM), a disease affecting the hearts ability to deliver oxygenated blood to the rest of the body. In many cases, DCM is idiopathic, with no clear cause. Idiopathic DCM is still poorly understood and manifests itself differently between patients, making it difficult to form early diagnosis, guide treatment plans, or inform therapeutic development. Our objective is to better understand different phenotypes of idiopathic DCM using patient-derived, induced pluripotent stem cell-cardiomyocytes (iPSC-CMs) to model DCM in a ;dish. We hypothesize that the phenotypic properties and underlying molecular mechanisms in DCM iPSC-CMs compared to age-matched controls can stratify DCM patients into defined disease subtypes. To achieve our objective, we aim to 1) generate iPSCs from both male and female DCM patients of varied ethnic backgrounds and differentiate them into CMs, 2) induce phenotypically immature patient-specific iPSC-CMs towards a more mature and disease-relevant phenotype, and 3) use high-content imaging to characterize phenotypic and morphological differences between iPSC-CMs from DCM patients and age-matched control subjects. This workflow will allow us to better understand DCM disease evolution and cluster idiopathic DCM patients into defined disease subtypes, paving the way for more personalized treatments, predicting individual responses to current therapies, and helping to identify novel drug targets to ultimately improve the quality and duration of life for idiopathic DCM patients.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jiang, Alyson
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~